Cannabis Use in Pregnancy: Reasons for Use

Katrina Mark, MD FACOG

Associate Professor Department of Obstetrics, Gynecology and Reproductive Medicine University of Maryland School of Medicine




Disclosure Information (Required)

Cannabis Use in Pregnancy: Person Centered Perspectives

April 1, 2022 10:30AM


Katrina Mark

No Disclosures





A djusted prevalence of past-month cannabis use





Volkow, JAMA 2019

What is a Cannabis Use Disorder?

	DSM-5 Substance Use Disorders ^c	
Hazardous use	X	ו
Social/interpersonal problems related to use	x	
Neglected major roles to use	x	
Legal problems	_	
Withdrawal ^d	x	
Tolerance	X	≥2
Used larger amounts/longer	x	criteria
Repeated attempts to quit/control use	x	
Much time spent using	x	
Physical/psychological problems related to use	x	
Activities given up to use	x	
Craving	X	J


Legal issues are no longer a criteria





Mild = 2-3 criteria Moderate = 4-6 criteria Severe = > 6 criteria

Hasin, Am J Psych 2013



Pregnancy considerations What is "hazardous use" Is there a such thing as "low risk use" in pregnancy? Social/interpersonal problems change Identifying withdrawal in pregnancy



Connor, Nat Dis Rev Primers 2021

CUD in pregnancy

Approximately ¼ of pregnant people who use at initiation of prenatal care will continue to use through the time of delivery

Continued use of a substance during pregnancy is pathognomonic for a use disorder.

- Adage is questioned with cannabis
- "Medical" cannabis use is not always easily defined







Reasons for use in pregnancy

Anonymous survey of pregnant people who screened positive for cannabis use by 4Ps Plus or urine toxicology

Asked reasons for use prior to and during pregnancy









■ Before pregnancy ■ During pregnancy









■ Non-medical/Recreational Only

Medical only

■ Mixed



Medical cannabis use in pregnancy

Currently no approved indications in pregnancy

Schedule 1 status does not allow for any well designed studies


Absence of evidence is not evidence of absence



Cannabis Withdrawal

Most common symptoms Anger, aggression, irritability Anxiety/nervousness Decreased appetite or weight loss Restlessness Sleep difficulties including strange dreams

Less common symptoms Chills Depressed mood Stomach pain/physical discomfort Shakiness Sweating





Cannabis Hyperemesis Syndrome


Nausea/vomiting and intense abdominal pain related to chronic cannabis use

Diagnostic characteristic	Frequency (%) (total <i>n</i> with criterion reported)	GRADE rating
History of regular cannabis use for years (over 1 year) [6, 16, 30, 51, 119, 120]	74.8 (179)	Low
Severe nausea and vomiting [16, 119, 120]	100 (211)	Low
Vomiting that recurs in a cyclic pattern over months [6, 30, 119, 121]	100 (211)	Low
Resolution of symptoms after stopping cannabis [6, 16, 30, 119-121]	96.8 (64)	Low
Reliable return of symptoms within weeks of resuming use [30]	а	Low
Compulsive hot baths with symptom relief [6, 16, 30, 51, 119-121]	92.3 (170)	Low
Male predominance [121]	72.9 (227)	Low
Abdominal pain [30, 119–121]	85.1 (202)	Low
At least weekly cannabis use [16, 120]	97.4 (197)	Low
History of daily cannabis use [121]	76.6 (197)	Low
Age less than 50 at onset of illness [16, 120, 121]	100 (227)	Low
Normal bowel habits [16]	a	Very low
Negative medical workup [16, 30, 119, 121]	a	Very low
Weight loss >5 kg [16, 120]	а	Very low

^a Criterion inconsistently documented in case reports, thus limiting frequency analysis



Sorensen, J Med Toxicol, 2017





Treatment of CUD

Motivational Interviewing/Motivational Enhancement Therapy
Cognitive Behavioral Therapy
Contingency Management
Social support counseling



Withdrawal

Important to educate patients that up to 50% of chronic users experience some symptoms of withdrawal

- Psychoeducation
- Coping skills training
- Pharmacologic agents proposed for symptomatic relief
 - Gabapentin
 - * Zolpidem
 - Nitrazepam (not in the US)
 - Dronabinol/nabiximols (not in US)



Recreational or Medical*?



N FOUNDED DISA PERIOD



A well-educated mind will always have more questions than answers.

— Helen Keller —



References (Required)

- Hasin D, O'Brien C, Auriacombe M, Borges G, Bucholz K, Budney A, Compton W, Crowley T, Ling W, Petry N, Schuckit M, Grant B. DSM-5 criteria for substance use disorders: Recommendations and rationale. Am J Psychiatry 2013" 170(8): 834-851.
- 2. Connor J, Stjepanovic D, LeFoll B, Hoch B, Hoch E, Budney A, Hall W. Cannaise use and use disorder. Nat Rev Dis Primers 2021; 7)1_: 16.
- **3.** Volkow N, Han B, Compton W, McCance-Katz E. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA 2019; 322(2): 167-169.
- 4. Budney A and Hughes J. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19(3): 233-238.
- 5. Sorensen C, DeSanto K, Borgelt L, Phillips K, Monte A. Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment – a systematic review. J Met Toxicol 2017; 13: 71-87.
- 6. Volkow N, Han B, Compton W, McCance-Katz E. Self-reported medical and nonmedical cannabis use among pregnant women in the United States. JAMA 2019; 322(2): 167-169.

